JP6877407B2 - Ｎｔｒｋ関連障害の治療に有用な化合物および組成物 - Google Patents

Ｎｔｒｋ関連障害の治療に有用な化合物および組成物 Download PDF

Info

Publication number
JP6877407B2
JP6877407B2 JP2018510406A JP2018510406A JP6877407B2 JP 6877407 B2 JP6877407 B2 JP 6877407B2 JP 2018510406 A JP2018510406 A JP 2018510406A JP 2018510406 A JP2018510406 A JP 2018510406A JP 6877407 B2 JP6877407 B2 JP 6877407B2
Authority
JP
Japan
Prior art keywords
mmol
mixture
tert
added
etoac
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2018510406A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018528200A5 (OSRAM
JP2018528200A (ja
Inventor
スティーブン マーク ウェングロウスキー，
スティーブン マーク ウェングロウスキー，
ナターシャ ブルージマンス，
ナターシャ ブルージマンス，
チャンドラセカール ブイ． ミドゥトゥル，
チャンドラセカール ブイ． ミドゥトゥル，
ニール ジュニア ビフルコ，
ニール ジュニア ビフルコ，
Original Assignee
ブループリント メディシンズ コーポレイション
ブループリント メディシンズ コーポレイション
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ブループリント メディシンズ コーポレイション, ブループリント メディシンズ コーポレイション filed Critical ブループリント メディシンズ コーポレイション
Publication of JP2018528200A publication Critical patent/JP2018528200A/ja
Publication of JP2018528200A5 publication Critical patent/JP2018528200A5/ja
Application granted granted Critical
Publication of JP6877407B2 publication Critical patent/JP6877407B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JP2018510406A 2015-08-26 2016-08-25 Ｎｔｒｋ関連障害の治療に有用な化合物および組成物 Expired - Fee Related JP6877407B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562210264P 2015-08-26 2015-08-26
US62/210,264 2015-08-26
PCT/US2016/048698 WO2017035354A1 (en) 2015-08-26 2016-08-25 Compounds and compositions useful for treating disorders related to ntrk

Publications (3)

Publication Number Publication Date
JP2018528200A JP2018528200A (ja) 2018-09-27
JP2018528200A5 JP2018528200A5 (OSRAM) 2019-09-12
JP6877407B2 true JP6877407B2 (ja) 2021-05-26

Family

ID=56896780

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018510406A Expired - Fee Related JP6877407B2 (ja) 2015-08-26 2016-08-25 Ｎｔｒｋ関連障害の治療に有用な化合物および組成物

Country Status (17)

Country Link
US (2) US10017512B2 (OSRAM)
EP (1) EP3341374A1 (OSRAM)
JP (1) JP6877407B2 (OSRAM)
KR (1) KR20180043810A (OSRAM)
CN (1) CN108137607B (OSRAM)
AR (1) AR105836A1 (OSRAM)
AU (1) AU2016311426B2 (OSRAM)
BR (1) BR112018003588A2 (OSRAM)
CA (1) CA2995997A1 (OSRAM)
HK (1) HK1255330A1 (OSRAM)
IL (1) IL257702A (OSRAM)
MX (1) MX2018002407A (OSRAM)
PH (1) PH12018500397A1 (OSRAM)
RU (1) RU2744974C2 (OSRAM)
TW (1) TW201713665A (OSRAM)
WO (1) WO2017035354A1 (OSRAM)
ZA (1) ZA201801881B (OSRAM)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SMT202100451T1 (it) 2012-07-11 2021-09-14 Blueprint Medicines Corp Inibitori del recettore di crescita dei fibroblasti
US9499522B2 (en) 2013-03-15 2016-11-22 Blueprint Medicines Corporation Compositions useful for treating disorders related to kit
BR112016008541B1 (pt) 2013-10-17 2022-11-22 Blueprint Medicines Corporation Composto ou sal farmaceuticamente aceitável, uso do mesmo para tratar mastocistose, tumor do estroma gastrointestinal e leucemia, e composição farmacêutica
AU2014339972B9 (en) 2013-10-25 2019-05-30 Blueprint Medicines Corporation Inhibitors of the fibroblast growth factor receptor
WO2015108992A1 (en) 2014-01-15 2015-07-23 Blueprint Medicines Corporation Heterobicyclic compounds and their use as fgfr4 receptor inhibitors
WO2016127074A1 (en) 2015-02-06 2016-08-11 Blueprint Medicines Corporation 2-(pyridin-3-yl)-pyrimidine derivatives as ret inhibitors
KR20180048635A (ko) 2015-07-24 2018-05-10 블루프린트 메디신즈 코포레이션 Kit 및 pdgfr에 관련된 장애를 치료하는데 유용한 조성물
RU2744974C2 (ru) 2015-08-26 2021-03-17 Блюпринт Медсинс Корпорейшн Соединения и композиции, применяемые для лечения расстройств, связанных с ntrk
IL302209B2 (en) 2015-11-02 2024-06-01 Blueprint Medicines Corp Inhibitors of ret
CA3005741A1 (en) 2015-11-19 2017-05-26 Blueprint Medicines Corporation Compounds and compositions useful for treating disorders related to ntrk
WO2017161269A1 (en) 2016-03-17 2017-09-21 Blueprint Medicines Corporation Inhibitors of ret receptor tyrosine kinases
EP4285996A3 (en) 2016-04-15 2024-01-10 Blueprint Medicines Corporation Inhibitors of activin receptor-like kinase
WO2018017983A1 (en) 2016-07-22 2018-01-25 Blueprint Medicines Corporation Compounds useful for treating disorders related to ret
US10035789B2 (en) 2016-07-27 2018-07-31 Blueprint Medicines Corporation Compounds useful for treating disorders related to RET
US11040979B2 (en) 2017-03-31 2021-06-22 Blueprint Medicines Corporation Substituted pyrrolo[1,2-b]pyridazines for treating disorders related to KIT and PDGFR
CN113735881A (zh) 2017-08-23 2021-12-03 正大天晴药业集团股份有限公司 含有氨基吡唑并嘧啶的大环化合物及其药物组合物和用途
CN111566102B (zh) 2017-10-18 2023-09-08 缆图药品公司 作为激活素受体样激酶抑制剂的取代的吡咯并吡啶
CN111936138B (zh) * 2018-02-05 2024-03-08 深圳市原力生命科学有限公司 作为ep4受体拮抗剂的杂二环化合物
CN111971287B (zh) * 2018-03-28 2023-06-02 重庆复尚源创医药技术有限公司 作为trk激酶抑制剂的大环化合物
PT3773589T (pt) 2018-04-03 2024-02-06 Blueprint Medicines Corp Inibidor de ret para utilização no tratamento de cancro com alteração de ret
KR20220012221A (ko) * 2019-02-27 2022-02-03 페로 테라퓨틱스 인코포레이티드 페롭토시스 유도 활성을 갖는 화합물 및 이의 사용 방법
EP3856341B1 (en) 2019-04-12 2023-09-06 Blueprint Medicines Corporation Crystalline forms of (s)-1-(4-fluorophenyl)-1-(2-(4-(6-(1-methyl-1h-pyrazol-4-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl)piperazinyl)-pyrimidin-5-yl)ethan-1-amine and methods of making
JP7787812B2 (ja) * 2019-11-25 2025-12-17 アルカームス インコーポレーテッド 置換大環状化合物および関連する治療方法
CA3183728A1 (en) 2020-05-29 2021-12-02 Blueprint Medicines Corporation Solid forms of pralsetinib
US11760747B2 (en) 2020-12-21 2023-09-19 Alkermes, Inc. Substituted piperidino compounds and related methods of treatment
CN113408945B (zh) * 2021-07-15 2023-03-24 广西中烟工业有限责任公司 一种烤烟纯度的检测方法、装置、电子设备及存储介质

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998014450A1 (en) * 1996-10-02 1998-04-09 Novartis Ag Pyrimidine derivatives and processes for the preparation thereof
PL224879B1 (pl) 2002-09-04 2017-02-28 Pharmacopeia Drug Discovery Inc Pirazolo [1,5-a] pirymidynowy związek, jego zastosowanie do wytwarzania leku oraz zawierająca go farmaceutyczna kompozycja
US7329662B2 (en) 2003-10-03 2008-02-12 Hoffmann-La Roche Inc. Pyrazolo-pyridine
EP2168968B1 (en) * 2004-04-02 2017-08-23 OSI Pharmaceuticals, LLC 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors
US8076338B2 (en) * 2004-04-23 2011-12-13 Exelixis, Inc. Kinase modulators and methods of use
WO2009032703A1 (en) * 2007-08-28 2009-03-12 Irm Llc 2- (het) arylamino-6-aminopyridine derivatives and fused forms thereof as anaplastic lymphoma kinase inhibitors
TR201807039T4 (tr) 2008-10-22 2018-06-21 Array Biopharma Inc Trk kinaz inhibitörleri olarak sübstitüe edilmiş pirazolo[1,5-]pirimidin bileşikleri.
AR077468A1 (es) 2009-07-09 2011-08-31 Array Biopharma Inc Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa
EP2566866A1 (en) * 2010-05-05 2013-03-13 Vertex Pharmaceuticals Incorporated 4 substituted pyrazolopyrimidines useful as pkc-theta inhibitors
WO2012034095A1 (en) 2010-09-09 2012-03-15 Irm Llc Compounds and compositions as trk inhibitors
UY33597A (es) 2010-09-09 2012-04-30 Irm Llc Compuestos y composiciones como inhibidores de la trk
CN102241678B (zh) 2011-04-26 2014-10-29 辽宁利锋科技开发有限公司 含有脂环结构化合物的抗肿瘤作用与应用
SMT202100451T1 (it) 2012-07-11 2021-09-14 Blueprint Medicines Corp Inibitori del recettore di crescita dei fibroblasti
US20150218652A1 (en) * 2012-08-31 2015-08-06 The Regents Of The Unversity Of Colorado, A Body Corporate Methods for diagnosis and treatment of cancer
JP6457942B2 (ja) 2012-10-05 2019-01-23 ライジェル ファーマシューティカルズ， インコーポレイテッド Ｇｄｆ−８阻害剤
HK1214830A1 (zh) 2012-11-05 2016-08-05 Foundation Medicine, Inc. 新型ntrk1融合分子及其应用
TWI629266B (zh) 2012-12-28 2018-07-11 藍印藥品公司 纖維母細胞生長因子受體之抑制劑
HK1222173A1 (zh) * 2013-02-01 2017-06-23 Bayer Pharma Aktiengesellschaft 取代的吡唑并嘧啶基氨基-吲唑类
CN103965199B (zh) 2013-02-02 2017-07-07 广东东阳光药业有限公司 一种芳杂环化合物、包含它的药物组合物及其用途
ES2674705T3 (es) 2013-02-21 2018-07-03 Calitor Sciences, Llc Compuestos heteroaromáticos como moduladores de la quinasa PI3
EP2970307B1 (en) 2013-03-13 2020-03-11 Genentech, Inc. Pyrazolo compounds and uses thereof
US9499522B2 (en) 2013-03-15 2016-11-22 Blueprint Medicines Corporation Compositions useful for treating disorders related to kit
GB2515785A (en) * 2013-07-03 2015-01-07 Redx Pharma Ltd Compounds
US9334263B2 (en) 2013-10-17 2016-05-10 Blueprint Medicines Corporation Compositions useful for treating disorders related to kit
BR112016008541B1 (pt) 2013-10-17 2022-11-22 Blueprint Medicines Corporation Composto ou sal farmaceuticamente aceitável, uso do mesmo para tratar mastocistose, tumor do estroma gastrointestinal e leucemia, e composição farmacêutica
AU2014339972B9 (en) 2013-10-25 2019-05-30 Blueprint Medicines Corporation Inhibitors of the fibroblast growth factor receptor
WO2015108992A1 (en) 2014-01-15 2015-07-23 Blueprint Medicines Corporation Heterobicyclic compounds and their use as fgfr4 receptor inhibitors
WO2015157093A1 (en) 2014-04-08 2015-10-15 Rigel Pharmaceuticals, Inc. 2,3-disubstituted pyridine compounds as tgf-beta inhibitors and methods of use
WO2016022569A1 (en) 2014-08-04 2016-02-11 Blueprint Medicines Corporation Compositions useful for treating disorders related to kit
HRP20240937T1 (hr) 2014-12-15 2024-10-25 Cmg Pharmaceutical Co., Ltd. Heteroaril spoj sa kondeziranim prstenom i njihova primjena kao trk inhibitora
WO2016127074A1 (en) 2015-02-06 2016-08-11 Blueprint Medicines Corporation 2-(pyridin-3-yl)-pyrimidine derivatives as ret inhibitors
WO2016133838A1 (en) 2015-02-20 2016-08-25 Rigel Pharmaceuticals, Inc. Gdf-8 inhibitors
KR20180048635A (ko) 2015-07-24 2018-05-10 블루프린트 메디신즈 코포레이션 Kit 및 pdgfr에 관련된 장애를 치료하는데 유용한 조성물
RU2744974C2 (ru) 2015-08-26 2021-03-17 Блюпринт Медсинс Корпорейшн Соединения и композиции, применяемые для лечения расстройств, связанных с ntrk
IL302209B2 (en) 2015-11-02 2024-06-01 Blueprint Medicines Corp Inhibitors of ret
CA3005741A1 (en) 2015-11-19 2017-05-26 Blueprint Medicines Corporation Compounds and compositions useful for treating disorders related to ntrk
WO2017161269A1 (en) 2016-03-17 2017-09-21 Blueprint Medicines Corporation Inhibitors of ret receptor tyrosine kinases
EP4285996A3 (en) 2016-04-15 2024-01-10 Blueprint Medicines Corporation Inhibitors of activin receptor-like kinase
WO2018017983A1 (en) 2016-07-22 2018-01-25 Blueprint Medicines Corporation Compounds useful for treating disorders related to ret
US10035789B2 (en) 2016-07-27 2018-07-31 Blueprint Medicines Corporation Compounds useful for treating disorders related to RET
US20190192522A1 (en) 2016-09-08 2019-06-27 Blueprint Medicines Corporation Inhibitors of the fibroblast growth factor receptor 4 in combination with cyclin-dependent kinase inhibitors
CN107844168B (zh) 2017-11-23 2020-12-01 英业达科技有限公司 主板组件及其卡扣装置

Also Published As

Publication number Publication date
MX2018002407A (es) 2018-11-29
IL257702A (en) 2018-04-30
AU2016311426A1 (en) 2018-04-05
ZA201801881B (en) 2019-05-29
HK1255330A1 (zh) 2019-08-16
BR112018003588A2 (pt) 2018-09-25
PH12018500397A1 (en) 2018-08-29
JP2018528200A (ja) 2018-09-27
CN108137607B (zh) 2021-04-06
CA2995997A1 (en) 2017-03-02
AU2016311426B2 (en) 2021-05-20
RU2744974C2 (ru) 2021-03-17
RU2018110379A3 (OSRAM) 2019-12-26
US20190169194A1 (en) 2019-06-06
CN108137607A (zh) 2018-06-08
KR20180043810A (ko) 2018-04-30
US11046697B2 (en) 2021-06-29
AR105836A1 (es) 2017-11-15
US10017512B2 (en) 2018-07-10
RU2018110379A (ru) 2019-09-27
WO2017035354A1 (en) 2017-03-02
TW201713665A (zh) 2017-04-16
US20170066773A1 (en) 2017-03-09
EP3341374A1 (en) 2018-07-04

Similar Documents

Publication Publication Date Title
JP6877407B2 (ja) Ｎｔｒｋ関連障害の治療に有用な化合物および組成物
TWI871397B (zh) Ｋｒａｓ突變蛋白抑制劑
CN113121530B (zh) 作为krasg12c突变蛋白抑制剂的吡啶酮并嘧啶类衍生物
JP6494624B2 (ja) カゼインキナーゼ１ｄ／ｅ阻害剤としての置換された４，５，６，７−テトラヒドロピラゾロ［１，５−ａ］ピラジン誘導体
TWI733713B (zh) 用於治療神經促進性酪氨酸受體激酶相關之異常的化合物與組成物
TWI751163B (zh) Ｆｇｆｒ４抑制劑、其製備方法和應用
JP2022525749A (ja) Ｊａｋキナーゼ阻害剤及びその調製方法、並びにその医薬分野での使用
TW201620900A (zh) １，３－苯并二呃衍生物
JP7278273B2 (ja) アクチビン受容体様キナーゼの阻害剤としての置換ピロロピリジン
CN117800975A (zh) 具有抗kras突变肿瘤活性的化合物
CN106687446A (zh) 作为t790m/wt‑egfr的选择性和不可逆的激酶抑制剂的5‑氨基‑4‑氨甲酰基‑吡唑化合物及其用途
JP2023536603A (ja) Ｆｇｆｒ阻害剤化合物及びその使用
JP2023522863A (ja) Ｅｇｆｒ阻害剤としての三環式化合物
EP3632903A1 (en) Compound used as autophagy regulator, and preparation method therefor and uses thereof
JP7041821B2 (ja) アミノ置換窒素含有縮合環化合物、その調製方法及び使用
JP2023522725A (ja) ３－アザビシクロアルキル誘導体およびこれを含む薬剤学的組成物
TW202525800A (zh) Ｒａｓ抑制劑
KR20250022815A (ko) Hpk1 억제제 및 이의 의약품에서의 응용
CN116425770A (zh) 作为Cdc7抑制剂的四并环类化合物
TW202216728A (zh) 一種噻吩並嘧啶類化合物、包含其藥物組合物及其應用
HK40065459A (en) Kras mutant protein inhibitors
HK40052926B (en) Kras mutant protein inhibitors
HK40052926A (en) Kras mutant protein inhibitors
CN113286594A (zh) 吡啶并嘧啶类化合物在制备治疗鼻咽癌药物中的应用
HK1237783B (zh) 作为t790m/wt-egfr的选择性和不可逆的激酶抑制剂的5-氨基-4-氨甲酰基-吡唑化合物及其用途

Legal Events

Date Code Title Description
RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20180830

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20180906

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20180830

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190801

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190801

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20200611

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200630

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20200914

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201224

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20210406

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20210427

R150 Certificate of patent or registration of utility model

Ref document number: 6877407

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE

Ref document number: 6877407

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees